Hematologic Malignancies and Cellular Therapy

Harry Paul Erba, MD, PhD

Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address harry.erba@duke.edu

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.  

Education and Training

  • Research Fellowship in Medicine, Medicine, Harvard Medical School, 1991 - 1993
  • Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital, 1991 - 1992
  • Clinical Fellow in Medicine, Medicine, Harvard Medical School, 1988 - 1991
  • Residency Physician, Medicine, Brigham and Women's Hospital, 1988 - 1990
  • Ph.D., Stanford University, 1988
  • M.D., Stanford University School of Medicine, 1988

Grants

Publications

Roboz, Gail J., Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.” Blood 135, no. 7 (February 13, 2020): 463–71. https://doi.org/10.1182/blood.2019002140.

PMID
31841594
Full Text

Merz, Lauren E., Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Ashley Crouch, Harry P. Erba, and Dale Bixby. “Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.” Clin Lymphoma Myeloma Leuk 20, no. 1 (January 2020): 24–30. https://doi.org/10.1016/j.clml.2019.09.615.

PMID
31711889
Full Text

Shanafelt, Tait D., Victoria Wang, Neil E. Kay, Curtis A. Hanson, Susan M. O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, et al. “Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.” Blood 134, no. Supplement_1 (November 13, 2019): 33. https://doi.org/10.1182/blood-2019-126824.

PMID
31723996
Full Text

Ustun, Celalettin, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, et al. “Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.” Leukemia 33, no. 11 (November 2019): 2599–2609. https://doi.org/10.1038/s41375-019-0477-x.

PMID
31073153
Full Text

Perl, Alexander E., Giovanni Martinelli, Jorge E. Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, et al. “Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.” N Engl J Med 381, no. 18 (October 31, 2019): 1728–40. https://doi.org/10.1056/NEJMoa1902688.

PMID
31665578
Full Text

Shah, Gaurav, Fady M. Mikhail, Kimo Bachiasvili, Pankit Vachhani, Harry P. Erba, and Nikolaos Papadantonakis. “Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.” Hematol Oncol Stem Cell Ther, October 14, 2019. https://doi.org/10.1016/j.hemonc.2019.08.006.

PMID
31629725
Full Text

DiNardo, Courtney D., Gail J. Roboz, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” In Clinical Lymphoma Myeloma and Leukemia, 19:S220–S220. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.07.094.

Full Text

Shanafelt, Tait D., Xin V. Wang, Neil E. Kay, Curtis A. Hanson, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, et al. “Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.” N Engl J Med 381, no. 5 (August 1, 2019): 432–43. https://doi.org/10.1056/NEJMoa1817073.

PMID
31365801
Full Text

Erba, Harry P., Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, and Eunice S. Wang. “Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.” Blood Adv 3, no. 13 (July 9, 2019): 1939–49. https://doi.org/10.1182/bloodadvances.2019030916.

PMID
31253596
Full Text

Roboz, Gail J., Courtney Denton Dinardo, Eytan M. Stein, Stephane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Scholars@Duke

Pages